SpeeDx Pty Ltd is seeking to commercialise its ResistancePlus® MABSC/MAC test, a rapid in vitro diagnostic tool to accurately and quickly identify bacterial infections related to Cystic Fibrosis, while using gene markers to predict antibiotic susceptibility or resistance.
SpeeDx Pty Ltd (SDx) is a privately-owned, Australian molecular diagnostics company that develop world-leading in-vitro-diagnostic (IVD) tests for infectious diseases and AMR using their proprietary PlexPCR™ and PlexPrim™ technologies.
Mycobacterium abscessus complex (MABSC) and Mycobacterium avium complex (MAC) are opportunistic pathogens that cause life-threatening respiratory infections, especially in immunocompromised patients such as those with lung conditions like cystic fibrosis (CF).
Treating infections is particularly challenging due to high antimicrobial resistance (AMR). Current reliance on slow culture-based diagnostic methods leaves doctors with little information and unable to quickly guide treatment decisions. Researchers at the University of Queensland (UQ) have developed a series of molecular qPCR tests for detecting MABSC and associated AMR.
Here, SDx and UQ are teaming up to commercialise UQ’s prototypes into a regulatory approved IVD product. Further, SDx will also apply this development pipeline to MAC. This product will diagnose MABSC, MAC and facilitate resistance-guided therapy faster than current methods, ultimately improving clinical management and outcomes for CF patients.
BTB Round: One
State: New South Wales
Project Partners: University of Queensland
- MTPConnect Grant: $358,922
- Industry Contribution: $388,922
Duration: April 2020 – June 2022
Contact: SpeeDx Enquiries